J. Goldman & Co’s Roivant Sciences ROIV Stock Holding History

J. Goldman & Co’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,307,543	Closed	-$13.8M	–	594
2024 Q2	$13.8M	Buy	+1,307,543	New	+$14.3M	0.39%	86

Other funds holding ROIV

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

J. Goldman & Co's ROIV Position: Q3 2024 in Review

J. Goldman & Co sold out of Roivant Sciences (ROIV) in Q3 2024, closing a stake of 1,307,543 shares — an estimated $13.8M sold.

J. Goldman & Co first reported a position in ROIV in Q2 2024 and held it in 1 quarter. The position peaked at $13.8M in Q2 2024. 293 funds tracked by Wall St. Rank hold ROIV as of Q3 2024.

J. Goldman & Co reported no remaining Roivant Sciences position as of Q3 2024 after selling out during the quarter.
J. Goldman & Co sold 1,307,543 Roivant Sciences shares in Q3 2024, an estimated $13.8M.
J. Goldman & Co first reported a position in Roivant Sciences in Q2 2024 and held it in 1 quarter.
J. Goldman & Co's Roivant Sciences position peaked at $13.8M in Q2 2024.
293 funds tracked by Wall St. Rank held Roivant Sciences as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.